Epitel, maker of a wearable electroencephalogram (EEG) system for seizure detection, introduced Wednesday it had scored $12.5 million in Sequence A funding.
The spherical was led by Catalyst Well being Ventures (CHV) and Genoa Ventures, with participation from Dexcom, OSF Ventures, Wavemaker 360, MedMountain Ventures and Salt Lake Metropolis Angels.
Earlier than the Sequence A, Epitel had introduced in additional than $7.5 million, largely from grant funding.
WHAT IT DOES
The corporate’s first product, the REMI system, consists of a wearable, wi-fi EEG sensor that is utilized under the hairline, and software program for suppliers to evaluation knowledge and monitor for seizures. The sensor can repeatedly monitor sufferers for 48 hours.
The platform received FDA 510(k) clearance for in-hospital use in March 2021, however Epitel plans to broaden into ambulatory and at-home care sooner or later.
WHAT IT’S FOR
The startup will use the inflow of capital from the Sequence A spherical for preliminary commercialization of its system and to proceed growing the platform.
“Epitel’s first FDA-cleared product, REMI, has the potential to revolutionize the analysis, remedy and administration of seizures inside the hospital. With Epitel, sufferers, irrespective of their geography, could have entry to important EEGs throughout essentially the most vital instances of want,” Epitel CEO Mark Lehmkuhle stated in an announcement.
“We intend to additional broaden our product pipeline to be used exterior the hospital by individuals dwelling with epilepsy and different seizure situations. We’re honored to have the assist of Catalyst Well being Ventures, Genoa Ventures, and a robust funding syndicate in our first financing.”
One other firm targeted on seizure detection is Zeit, which introduced in November it had raised $2 million in seed funding. The corporate makes a scarf gadget that goals to alert sufferers to indicators of a stroke or seizure. Zeit stated the seed funding would go towards hiring new group members and funding a submission to the FDA.
Distant monitoring firm Empatica makes an FDA-cleared wrist-worn gadget for individuals with epilepsy to alert customers and their caregivers of convulsive seizures.
NeuroPace, which additionally makes an implantable device for patients with uncontrolled epilepsy, launched a platform last year that works with its system to gather knowledge about sufferers’ seizures to personalize their care.